Bevixa is a Bevacizumab injection — a VEGF-A inhibiting monoclonal antibody — manufactured by Incepta Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Bevixa contains the same active molecule found in Avastin® (Roche/Genentech) and is dispensed under the Named Patient Program.

Because bevacizumab is a large biologic molecule requiring cold-chain storage and IV or intravitreal administration, Bevixa is intended for procurement by clinics, hospitals, and oncology treatment centres — not for direct home delivery to individual patients.

Tumours require a constant new blood supply (angiogenesis) to grow and metastasise, driven substantially by a protein called Vascular Endothelial Growth Factor-A (VEGF-A).

Bevacizumab carries several serious warnings that require monitoring, particularly around bleeding, wound healing, and gastrointestinal perforation.

Bevixa is administered exclusively by trained healthcare staff in a clinical setting — it is never self-administered.

• Intravenous infusion (oncology): Dosing and schedule are determined by the specific cancer type and chemotherapy regimen your oncologist has prescribed. Typical infusions take 30–90 minutes and are given every 2–3 weeks, depending on protocol.
• Intravitreal injection (ophthalmology): Used off-label by some ophthalmologists for wet age-related macular degeneration, administered directly into the eye by a specialist. Dosing and frequency are determined by the treating ophthalmologist.
• Pre-treatment requirements: Surgery should be avoided within 28 days before or after treatment due to wound-healing risk; blood pressure and urine protein are typically checked before each infusion.